{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-002070","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.623554+00:00","generated_at":"2026-05-28T07:16:25.943979+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"60 Degrees Pharmaceuticals enrolls first patient in expanded access study of tafenoquine for persistent babesiosis","bullets":["First patient enrolled in NCT06478641, an expanded access study of tafenoquine for persistent babesiosis after standard-of-care failure.","Prior case series in Clinical Infectious Diseases reported 80% cure rate with tafenoquine plus SOC in five high-risk patients.","Company estimates cumulative U.S. accessible market for ARAKODA (tafenoquine) in babesiosis may exceed 400,000 patients through Dec 2035.","Tafenoquine is FDA-approved for malaria prophylaxis (ARAKODA) but not proven effective or approved for babesiosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-002070","json":"https://secwatch.observer/filing/0001213900-25-002070.json","markdown":"https://secwatch.observer/filing/0001213900-25-002070.md","text":"https://secwatch.observer/filing/0001213900-25-002070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025002070/0001213900-25-002070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025002070/ea0227197-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T07:16:25.943979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}